GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

Corix Bioscience CXBS · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.00

—

Close of 30 Oct 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2016

Revenue

$693,621

FY2014FY2016

Net income

−$4.4m

FY2014FY2016

Free cash flow

−$1.9m

FY2014FY2016

Shareholders' equity

$4.5m

FY2014FY2016

Income statement

Fiscal years

FY2016FY2015FY2014
Revenue$693,621$482,426—
Gross profit$693,621$482,426—
Operating income−$4.0m−$2.6m−$54,046
Net income−$4.4m−$2.8m−$57,153
Diluted earnings per share-38.15-23.83-0.49

Balance sheet

At each fiscal year end

FY2016FY2015FY2014
Total assets$11.4m$9.4m$461
Total liabilities$6.9m$4.9m—
Debt$5.1m$4.3m—
Shareholders' equity$4.5m$4.5m—
Shares outstanding0m0m0m

Cash flow

Fiscal years

FY2016FY2015FY2014
Cash from operations−$1.8m−$2.5m−$20,439
Capital spending−$27,504−$1.0m−$1.0m
Free cash flow−$1.9m−$3.5m−$1.0m

Latest quarters

By quarter end

Sept 2017Jun 2017Mar 2017Dec 2016Sept 2016Jun 2016Mar 2016Dec 2015
Revenue———$693,621—$170,000$160,000$150,000
Gross profit———$693,621————
Operating income−$299,954−$696,126−$379,724−$3.1m−$327,555−$1.8m−$730,000−$410,000
Net income−$3.1m−$2.2m−$1.2m−$139,081−$1.5m−$1.9m−$790,000−$470,000
Diluted earnings per share-0.34-0.23-0.13-0.02-0.17-0.24-0.10-0.09
Cash from operations−$1.0m———————
Total assets$4.3m$10.5m$0$11.4m$12.1m$10.6m$9.0m$9.4m
Cash and short-term investments————$90,700$10,000$80,000$200,000
Debt———$5.1m$5.3m$5.1m$4.3m$4.3m
Shareholders' equity$3.6m$6.5m$0$4.5m$4.4m$4.5m$4.0m$4.5m

Growth per year

Compound annual rate

3 years5 years10 years
Operating income599.8%127.0%—
Net income37.0%125.3%—

Average margins

Over each period

1 year3 years5 years10 years
Gross margin100.0%———

Valuation history

At each fiscal year end

FY2014
Price to earnings-0.0

Share price return

Finished calendar years

2025202420232022202120202019201820172016
Return0%0%0%900%-100%32400%-63%281%125%-100%

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years.

  • 1000-to-1 reverse split · 10 Jun 2015
  • 775-to-1 reverse split · 21 Feb 2014
  • 20-for-1 split · 30 Jan 2009

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.